<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03283319</url>
  </required_header>
  <id_info>
    <org_study_id>BP-I-17-002</org_study_id>
    <secondary_id>HHSO100201400004I</secondary_id>
    <secondary_id>TO# HHSO10033001T</secondary_id>
    <nct_id>NCT03283319</nct_id>
  </id_info>
  <brief_title>Panblok H7 Vaccine Adjuvanted With AS03 or MF59</brief_title>
  <official_title>Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03® or MF59®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rho, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biomedical Advanced Research and Development Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess the safety and ability of a Panblok H7 influenza&#xD;
      vaccine adjuvanted with AS03 or MF59 to generate an immune response after 2 doses separated&#xD;
      by 28 days. Three different antigen dose levels of Panblok H7 will be tested.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blinded, phase 2 study to assess safety and immunogenicity of&#xD;
      Panblok H7 vaccine at three antigen dose levels (3.75, 7.5, and 15 μg) adjuvanted with AS03&#xD;
      or MF59. The main purpose of this study is to assess the safety and ability of the&#xD;
      recombinant Panblok H7 influenza vaccine adjuvanted with AS03 or MF59 to generate an immune&#xD;
      response after 2 doses separated by 28 days in healthy males and nonpregnant females, aged 18&#xD;
      to 49 years, inclusive. The expected study duration is approximately 13.5 months per&#xD;
      participant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2017</start_date>
  <completion_date type="Actual">November 9, 2018</completion_date>
  <primary_completion_date type="Actual">December 15, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to one of the six treatment groups at Day 1 and will receive the assigned dose of antigen and adjuvant on Day 1 and Day 29.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited Local Reactogenicity Symptoms for Participants Given Adjuvant AS03</measure>
    <time_frame>Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)</time_frame>
    <description>Count of participants who experienced at least one of the following during at least one of the time frames specified:&#xD;
Solicited local reactions at the injection site: erythema/redness, induration/swelling, and pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited Systemic Reactogenicity Symptoms for Participants Given Adjuvant AS03</measure>
    <time_frame>Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)</time_frame>
    <description>Count of participants who experienced at least one of the following during at least one of the time frames specified:&#xD;
Solicited systemic reactions include fever, myalgia (muscle pain), arthralgia (joint pain), fatigue, headache, nausea, vomiting, diarrhea, and chills.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited Local Reactogenicity Symptoms for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)</time_frame>
    <description>Count of participants who experienced at least one of the following during at least one of the time frames specified:&#xD;
Solicited local reactions at the injection site: erythema/redness, induration/swelling, and pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited Systemic Reactogenicity Symptoms for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)</time_frame>
    <description>Count of participants who experienced at least one of the following during at least one of the time frames specified:&#xD;
Solicited systemic reactions include fever, myalgia (muscle pain), arthralgia (joint pain), fatigue, headache, nausea, vomiting, diarrhea, and chills.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Day 50</time_frame>
    <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 50</time_frame>
    <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Day 50</time_frame>
    <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 50</time_frame>
    <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Serious Adverse Events (SAEs) for Participants Given Adjuvant AS03</measure>
    <time_frame>Day 1 through Day 394</time_frame>
    <description>Count of participants who experienced at least one serious adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Serious Adverse Events (SAEs) for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 1 through Day 394</time_frame>
    <description>Count of participants who experienced at least one serious adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Medically Attended Adverse Events (MAAEs) for Participants Given Adjuvant AS03</measure>
    <time_frame>Day 1 through Day 394</time_frame>
    <description>Count of participants who experienced at least one adverse event that requires a visit to medical personnel, including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason occurring post-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Medically Attended Adverse Events (MAAEs) for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 1 through Day 394</time_frame>
    <description>Count of participants who experienced at least one adverse event that requires a visit to medical personnel, including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason occurring post-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs) for Participants Given Adjuvant AS03</measure>
    <time_frame>Day 1 through Day 394</time_frame>
    <description>Count of participants who experienced at least one medical condition that was potentially immune mediated occurring post-vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs) for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 1 through Day 394</time_frame>
    <description>Count of participants who experienced at least one medical condition that was potentially immune mediated occurring post-vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Unsolicited Adverse Events for Participants Given Adjuvant AS03</measure>
    <time_frame>Day 1 through Day 53, which is the upper window of the Day 50 visit</time_frame>
    <description>Count of participants who experienced at least one unsolicited adverse event (i.e. adverse events not included in the solicited local and systemic adverse event list nor considered a serious AE, MAAE or PIMMC ) that occur post-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Unsolicited Adverse Events for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 1 through Day 50</time_frame>
    <description>Count of participants who experienced at least one unsolicited adverse event (i.e. adverse events not included in the solicited local and systemic adverse event list nor considered a serious AE, MAAE or PIMMC) that occur post-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Day 50</time_frame>
    <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 50</time_frame>
    <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Day 50</time_frame>
    <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
    <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 50</time_frame>
    <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Days 29, 50, 121, and 212</time_frame>
    <description>The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer &lt;1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
    <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 50</time_frame>
    <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
    <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Day 50</time_frame>
    <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
    <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 50</time_frame>
    <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Screening, Day 29, Day 121, Day 212</time_frame>
    <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Screening, Day 29, Day 121, Day 212</time_frame>
    <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Screening, Day 29, Day 121, Day 212</time_frame>
    <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Screening, Day 29, Day 121, Day 212</time_frame>
    <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Day 29, Day 50, Day 121, Day 212</time_frame>
    <description>The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer &lt;1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 29, Day 50, Day 121, Day 212</time_frame>
    <description>The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer &lt;1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Day 29, Day 50, Day 121, Day 212</time_frame>
    <description>The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer &lt;1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 29, Day 50, Day 121, Day 212</time_frame>
    <description>The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer &lt;1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 29, Day 50, Day 121, Day 212</time_frame>
    <description>The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer &lt;1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Day 29, Day 50, Day 121, Day 212</time_frame>
    <description>The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer &lt;1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Day 29, Day 50, Day 121, Day 212</time_frame>
    <description>The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer &lt;1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Day 50</time_frame>
    <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Microneutralization (MN) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
    <description>Serum MN antibody titers against the H7 antigen (protein) contained in the vaccine. A higher MN titer means a better immune response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Microneutralization (MN) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
    <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Microneutralization (MN) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03</measure>
    <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
    <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Microneutralization (MN) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59</measure>
    <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
    <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">366</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>3.75 ug Panblok H7 plus AS03</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 plus AS03</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5 ug Panblok H7 plus AS03</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with AS03</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 ug Panblok H7 plus AS03</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with AS03</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.75 ug Panblok H7 plus MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 adjuvanted with MF59</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5 ug Panblok H7 plus MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with MF59</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 ug Panblok H7 plus MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with MF59</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3.75 ug Panblok H7</intervention_name>
    <description>0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.</description>
    <arm_group_label>3.75 ug Panblok H7 plus AS03</arm_group_label>
    <arm_group_label>3.75 ug Panblok H7 plus MF59</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7.5 ug Panblok H7</intervention_name>
    <description>Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.</description>
    <arm_group_label>7.5 ug Panblok H7 plus AS03</arm_group_label>
    <arm_group_label>7.5 ug Panblok H7 plus MF59</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>15 ug Panblok H7</intervention_name>
    <description>Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.</description>
    <arm_group_label>15 ug Panblok H7 plus AS03</arm_group_label>
    <arm_group_label>15 ug Panblok H7 plus MF59</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59</intervention_name>
    <description>0.5 mL MF59 (39 mg squalene/mL ) adjuvant.</description>
    <arm_group_label>15 ug Panblok H7 plus MF59</arm_group_label>
    <arm_group_label>3.75 ug Panblok H7 plus MF59</arm_group_label>
    <arm_group_label>7.5 ug Panblok H7 plus MF59</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AS03</intervention_name>
    <description>0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.</description>
    <arm_group_label>15 ug Panblok H7 plus AS03</arm_group_label>
    <arm_group_label>3.75 ug Panblok H7 plus AS03</arm_group_label>
    <arm_group_label>7.5 ug Panblok H7 plus AS03</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or nonpregnant female 18 to 49 years of age, inclusive, at the time of the first&#xD;
             study vaccination.&#xD;
&#xD;
          2. Provide written informed consent prior to the initiation of any study-related&#xD;
             procedures.&#xD;
&#xD;
          3. Are able to understand and comply with planned study procedures.&#xD;
&#xD;
          4. Have a stable health status based on site investigator's clinical judgment, as&#xD;
             established by physical examination, vital signs, and medical history.&#xD;
&#xD;
          5. Have access to a consistent and reliable means of telephone contact, which may be in&#xD;
             the home, workplace, or by personal mobile electronic device.&#xD;
&#xD;
          6. Agree to stay in contact with the study site for the duration of the study, have no&#xD;
             current plans to move from the study area, and agree to provide updated contact&#xD;
             information as necessary.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have had a prior severe reaction to any influenza vaccine or have a known allergy to&#xD;
             squalene-based adjuvants.&#xD;
&#xD;
          2. Women who are pregnant or breast feeding. Women of childbearing potential must have a&#xD;
             negative urine pregnancy test at screening and within 24 hours prior to each&#xD;
             vaccination.&#xD;
&#xD;
             Women of childbearing potential are defined as postmenarcheal and premenopausal&#xD;
             females capable of becoming pregnant. This does not include females who meet any of&#xD;
             the following conditions: menopausal &gt;12 months, tubal ligation &gt;12 months, bilateral&#xD;
             salpingo-oophorectomy, or hysterectomy.&#xD;
&#xD;
          3. Women of childbearing potential who refuse to use an acceptable method of birth&#xD;
             control from screening to Day 50 (Visit 7) or, if sexually active with a male partner,&#xD;
             who have not used a reliable birth control method during the 2 months prior to&#xD;
             screening.&#xD;
&#xD;
             Adequate contraception is defined as a contraceptive method with a failure rate of&#xD;
             less than 1% per year when used consistently and correctly and when applicable, in&#xD;
             accordance with the product label, for example: abstinence from penile-vaginal&#xD;
             intercourse; oral contraceptives, either combined or progestogen alone; injectable&#xD;
             progestogen; implants of etonogestrel or levonorgestrel; estrogenic vaginal ring;&#xD;
             percutaneous contraceptive patches; intrauterine device or intrauterine system; male&#xD;
             partner sterilization at least 6 months prior to the female participant's Screening&#xD;
             Visit, and this male is the sole partner for that participant (the information on the&#xD;
             male partner's sterility can come from the site personnel's review of the participant&#xD;
             medical records or interview with the participant on her medical history); male condom&#xD;
             combined with a vaginal spermicide (foam, gel, film, cream, or suppository); male&#xD;
             condom combined with a female diaphragm, either with or without a vaginal spermicide&#xD;
             (foam, gel, film, cream, or suppository).&#xD;
&#xD;
          4. Have immunosuppression as a result of an underlying illness or treatment, or use of&#xD;
             anticancer chemotherapy or radiation therapy (cytotoxic) within the preceding 36&#xD;
             months, or plans to receive immunosuppressive therapy/cytotoxic treatment during study&#xD;
             participation.&#xD;
&#xD;
          5. Have an active neoplastic disease or a history of any hematologic malignancy. However,&#xD;
             participants with superficial skin cancer who do not require intervention other than&#xD;
             local excision are not excluded.&#xD;
&#xD;
          6. Have long-term use (≥14 consecutive days) of glucocorticoids including oral or&#xD;
             parenteral prednisone or prednisone equivalent (&gt;20 mg total dose per day) or&#xD;
             high-dose inhaled steroids (&gt;800 µg/day of beclomethasone dipropionate or equivalent)&#xD;
             within 1 month prior to screening in this study. However, participants on low-dose&#xD;
             inhaled steroids (≤800 µg/day of beclomethasone dipropionate or equivalent) or topical&#xD;
             steroids are not excluded.&#xD;
&#xD;
          7. History of schizophrenia, bipolar disease, psychosis, or severe personality disorder.&#xD;
&#xD;
          8. History of hospitalization for psychiatric illness, attempted suicide, or having been&#xD;
             deemed a danger to self or others within the past 10 years.&#xD;
&#xD;
          9. Have received immunoglobulin or other blood product (with the exception of Rho[D]&#xD;
             immune globulin) within the 3 months prior to screening in this study.&#xD;
&#xD;
         10. Have received any live vaccines within 4 weeks or inactivated or recombinant protein&#xD;
             vaccines within 2 weeks prior to screening in this study or plan to receive such&#xD;
             vaccines (including seasonal influenza vaccines) from screening through 21 days&#xD;
             following the second dose of the study vaccine (Screening Visit through Day 50).&#xD;
&#xD;
         11. Have an acute or chronic medical condition that, in the opinion of the site&#xD;
             investigator, would render vaccination unsafe or would interfere with the evaluation&#xD;
             of responses. This includes all PIMMCs such as Guillain Barré syndrome, narcolepsy,&#xD;
             and current or history of autoimmune or chronic inflammatory disease.&#xD;
&#xD;
         12. Have an acute illness, including body temperature greater than 100.4°F, at screening,&#xD;
             immediately prior to each vaccination or, per participant report, within 3 days prior&#xD;
             to each vaccination in this study.&#xD;
&#xD;
         13. Received an experimental agent (vaccine, drug, biologic, device, blood product, or&#xD;
             medication) within 1 month prior to screening in this study or expect to receive an&#xD;
             experimental agent during the study period.&#xD;
&#xD;
         14. Are participating or plan to participate in another interventional clinical trial&#xD;
             (either active or follow up phase) during the study period.&#xD;
&#xD;
         15. Participated in an A(H7) influenza vaccine study in the past or have a history of&#xD;
             A(H7) influenza infection prior to vaccination in this study.&#xD;
&#xD;
         16. Have known human immunodeficiency virus, hepatitis B, or hepatitis C infection (based&#xD;
             on medical history).&#xD;
&#xD;
         17. Have a history of alcohol or drug abuse in the last 5 years.&#xD;
&#xD;
         18. Have a body mass index &gt;35 kg/m2.&#xD;
&#xD;
         19. Have a first degree relative with narcolepsy.&#xD;
&#xD;
         20. Have any laboratory test result or clinical findings (including vital signs) that&#xD;
             singly or in combination are likely to unfavorably alter the risk-benefit of&#xD;
             participation or to confound study safety or immunogenicity results. participants&#xD;
             cannot be rescreened based on abnormal laboratory test results.&#xD;
&#xD;
         21. Alanine aminotransferase (AST) &gt;2 times the upper limit of normal (ULN), or bilirubin&#xD;
             &gt;1.5 times the ULN unless isolated Gilbert's syndrome. participants cannot be&#xD;
             rescreened based on abnormal laboratory test results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Adams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Kentucky Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rochester Clinical Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Fierro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johnson County Clin-Trials</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Terry Poling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heartland Research Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 12, 2017</study_first_submitted>
  <study_first_submitted_qc>September 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2017</study_first_posted>
  <results_first_submitted>August 28, 2019</results_first_submitted>
  <results_first_submitted_qc>September 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2019</results_first_posted>
  <disposition_first_submitted>February 14, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>February 14, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 11, 2019</disposition_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>human</keyword>
  <keyword>Influenza in Birds</keyword>
  <keyword>Orthomyxoviridae Infections</keyword>
  <keyword>RNA Virus Infections</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Respiratory Tract Infections</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>MF59</keyword>
  <keyword>AS03</keyword>
  <keyword>Adjuvants</keyword>
  <keyword>Immunologic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT03283319/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT03283319/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>3.75 µg Panblok H7 Plus AS03</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
        </group>
        <group group_id="P2">
          <title>7.5 µg Panblok H7 Plus AS03</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
        </group>
        <group group_id="P3">
          <title>15 µg Panblok H7 Plus AS03</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
        </group>
        <group group_id="P4">
          <title>3.75 µg Panblok H7 Plus MF59</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
        </group>
        <group group_id="P5">
          <title>7.5 µg Panblok H7 Plus MF59</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
        </group>
        <group group_id="P6">
          <title>15 µg Panblok H7 Plus MF59</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="60"/>
                <participants group_id="P6" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="56"/>
                <participants group_id="P6" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>BARDA regulatory agency or IRB decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>3.75 µg Panblok H7 Plus AS03</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
        </group>
        <group group_id="B2">
          <title>7.5 µg Panblok H7 Plus AS03</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
        </group>
        <group group_id="B3">
          <title>15 µg Panblok H7 Plus AS03</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
        </group>
        <group group_id="B4">
          <title>3.75 µg Panblok H7 Plus MF59</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
        </group>
        <group group_id="B5">
          <title>7.5 µg Panblok H7 Plus MF59</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
        </group>
        <group group_id="B6">
          <title>15 µg Panblok H7 Plus MF59</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="62"/>
            <count group_id="B4" value="61"/>
            <count group_id="B5" value="60"/>
            <count group_id="B6" value="61"/>
            <count group_id="B7" value="366"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="60"/>
                    <measurement group_id="B6" value="61"/>
                    <measurement group_id="B7" value="363"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.8" spread="7.92"/>
                    <measurement group_id="B2" value="34.3" spread="9.14"/>
                    <measurement group_id="B3" value="35.8" spread="9.29"/>
                    <measurement group_id="B4" value="35" spread="9.58"/>
                    <measurement group_id="B5" value="37.1" spread="7.66"/>
                    <measurement group_id="B6" value="35.8" spread="8.53"/>
                    <measurement group_id="B7" value="35.4" spread="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="35"/>
                    <measurement group_id="B7" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="58"/>
                    <measurement group_id="B6" value="57"/>
                    <measurement group_id="B7" value="344"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="53"/>
                    <measurement group_id="B7" value="291"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="60"/>
                    <measurement group_id="B6" value="61"/>
                    <measurement group_id="B7" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Solicited Local Reactogenicity Symptoms for Participants Given Adjuvant AS03</title>
        <description>Count of participants who experienced at least one of the following during at least one of the time frames specified:&#xD;
Solicited local reactions at the injection site: erythema/redness, induration/swelling, and pain</description>
        <time_frame>Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)</time_frame>
        <population>Safety population includes all participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited Local Reactogenicity Symptoms for Participants Given Adjuvant AS03</title>
          <description>Count of participants who experienced at least one of the following during at least one of the time frames specified:&#xD;
Solicited local reactions at the injection site: erythema/redness, induration/swelling, and pain</description>
          <population>Safety population includes all participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Solicited Systemic Reactogenicity Symptoms for Participants Given Adjuvant AS03</title>
        <description>Count of participants who experienced at least one of the following during at least one of the time frames specified:&#xD;
Solicited systemic reactions include fever, myalgia (muscle pain), arthralgia (joint pain), fatigue, headache, nausea, vomiting, diarrhea, and chills.</description>
        <time_frame>Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)</time_frame>
        <population>Safety population includes all participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited Systemic Reactogenicity Symptoms for Participants Given Adjuvant AS03</title>
          <description>Count of participants who experienced at least one of the following during at least one of the time frames specified:&#xD;
Solicited systemic reactions include fever, myalgia (muscle pain), arthralgia (joint pain), fatigue, headache, nausea, vomiting, diarrhea, and chills.</description>
          <population>Safety population includes all participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Solicited Local Reactogenicity Symptoms for Participants Given Adjuvant MF59</title>
        <description>Count of participants who experienced at least one of the following during at least one of the time frames specified:&#xD;
Solicited local reactions at the injection site: erythema/redness, induration/swelling, and pain</description>
        <time_frame>Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)</time_frame>
        <population>Safety population includes all participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited Local Reactogenicity Symptoms for Participants Given Adjuvant MF59</title>
          <description>Count of participants who experienced at least one of the following during at least one of the time frames specified:&#xD;
Solicited local reactions at the injection site: erythema/redness, induration/swelling, and pain</description>
          <population>Safety population includes all participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Solicited Systemic Reactogenicity Symptoms for Participants Given Adjuvant MF59</title>
        <description>Count of participants who experienced at least one of the following during at least one of the time frames specified:&#xD;
Solicited systemic reactions include fever, myalgia (muscle pain), arthralgia (joint pain), fatigue, headache, nausea, vomiting, diarrhea, and chills.</description>
        <time_frame>Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)</time_frame>
        <population>Safety population includes all participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited Systemic Reactogenicity Symptoms for Participants Given Adjuvant MF59</title>
          <description>Count of participants who experienced at least one of the following during at least one of the time frames specified:&#xD;
Solicited systemic reactions include fever, myalgia (muscle pain), arthralgia (joint pain), fatigue, headache, nausea, vomiting, diarrhea, and chills.</description>
          <population>Safety population includes all participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03</title>
        <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
        <time_frame>Day 50</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03</title>
          <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59</title>
        <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
        <time_frame>Day 50</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59</title>
          <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03</title>
        <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
        <time_frame>Day 50</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03</title>
          <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59</title>
        <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
        <time_frame>Day 50</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59</title>
          <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Serious Adverse Events (SAEs) for Participants Given Adjuvant AS03</title>
        <description>Count of participants who experienced at least one serious adverse event</description>
        <time_frame>Day 1 through Day 394</time_frame>
        <population>Safety population includes all participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Serious Adverse Events (SAEs) for Participants Given Adjuvant AS03</title>
          <description>Count of participants who experienced at least one serious adverse event</description>
          <population>Safety population includes all participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Serious Adverse Events (SAEs) for Participants Given Adjuvant MF59</title>
        <description>Count of participants who experienced at least one serious adverse event</description>
        <time_frame>Day 1 through Day 394</time_frame>
        <population>Safety population includes all participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Serious Adverse Events (SAEs) for Participants Given Adjuvant MF59</title>
          <description>Count of participants who experienced at least one serious adverse event</description>
          <population>Safety population includes all participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Medically Attended Adverse Events (MAAEs) for Participants Given Adjuvant AS03</title>
        <description>Count of participants who experienced at least one adverse event that requires a visit to medical personnel, including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason occurring post-vaccination.</description>
        <time_frame>Day 1 through Day 394</time_frame>
        <population>Safety population includes all participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Medically Attended Adverse Events (MAAEs) for Participants Given Adjuvant AS03</title>
          <description>Count of participants who experienced at least one adverse event that requires a visit to medical personnel, including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason occurring post-vaccination.</description>
          <population>Safety population includes all participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Medically Attended Adverse Events (MAAEs) for Participants Given Adjuvant MF59</title>
        <description>Count of participants who experienced at least one adverse event that requires a visit to medical personnel, including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason occurring post-vaccination.</description>
        <time_frame>Day 1 through Day 394</time_frame>
        <population>Safety population includes all participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Medically Attended Adverse Events (MAAEs) for Participants Given Adjuvant MF59</title>
          <description>Count of participants who experienced at least one adverse event that requires a visit to medical personnel, including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason occurring post-vaccination.</description>
          <population>Safety population includes all participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs) for Participants Given Adjuvant AS03</title>
        <description>Count of participants who experienced at least one medical condition that was potentially immune mediated occurring post-vaccination</description>
        <time_frame>Day 1 through Day 394</time_frame>
        <population>Safety population includes all participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs) for Participants Given Adjuvant AS03</title>
          <description>Count of participants who experienced at least one medical condition that was potentially immune mediated occurring post-vaccination</description>
          <population>Safety population includes all participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs) for Participants Given Adjuvant MF59</title>
        <description>Count of participants who experienced at least one medical condition that was potentially immune mediated occurring post-vaccination</description>
        <time_frame>Day 1 through Day 394</time_frame>
        <population>Safety population includes all participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs) for Participants Given Adjuvant MF59</title>
          <description>Count of participants who experienced at least one medical condition that was potentially immune mediated occurring post-vaccination</description>
          <population>Safety population includes all participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Unsolicited Adverse Events for Participants Given Adjuvant AS03</title>
        <description>Count of participants who experienced at least one unsolicited adverse event (i.e. adverse events not included in the solicited local and systemic adverse event list nor considered a serious AE, MAAE or PIMMC ) that occur post-vaccination.</description>
        <time_frame>Day 1 through Day 53, which is the upper window of the Day 50 visit</time_frame>
        <population>Safety population includes all participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Unsolicited Adverse Events for Participants Given Adjuvant AS03</title>
          <description>Count of participants who experienced at least one unsolicited adverse event (i.e. adverse events not included in the solicited local and systemic adverse event list nor considered a serious AE, MAAE or PIMMC ) that occur post-vaccination.</description>
          <population>Safety population includes all participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Unsolicited Adverse Events for Participants Given Adjuvant MF59</title>
        <description>Count of participants who experienced at least one unsolicited adverse event (i.e. adverse events not included in the solicited local and systemic adverse event list nor considered a serious AE, MAAE or PIMMC) that occur post-vaccination.</description>
        <time_frame>Day 1 through Day 50</time_frame>
        <population>Safety population includes all participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Unsolicited Adverse Events for Participants Given Adjuvant MF59</title>
          <description>Count of participants who experienced at least one unsolicited adverse event (i.e. adverse events not included in the solicited local and systemic adverse event list nor considered a serious AE, MAAE or PIMMC) that occur post-vaccination.</description>
          <population>Safety population includes all participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03</title>
        <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
        <time_frame>Day 50</time_frame>
        <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03</title>
          <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
          <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59</title>
        <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
        <time_frame>Day 50</time_frame>
        <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59</title>
          <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
          <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03</title>
        <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
        <time_frame>Day 50</time_frame>
        <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03</title>
          <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
          <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03</title>
        <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
        <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03</title>
          <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="5.0" upper_limit="5.2"/>
                    <measurement group_id="O2" value="5.3" lower_limit="5.0" upper_limit="5.7"/>
                    <measurement group_id="O3" value="5.5" lower_limit="5.1" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="7" upper_limit="10.8"/>
                    <measurement group_id="O2" value="12.3" lower_limit="9.4" upper_limit="16"/>
                    <measurement group_id="O3" value="12.4" lower_limit="9.2" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297.1" lower_limit="216.5" upper_limit="407.7"/>
                    <measurement group_id="O2" value="438.3" lower_limit="329.4" upper_limit="583"/>
                    <measurement group_id="O3" value="505.9" lower_limit="399.7" upper_limit="640.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" lower_limit="43.9" upper_limit="78.8"/>
                    <measurement group_id="O2" value="73" lower_limit="55.5" upper_limit="96"/>
                    <measurement group_id="O3" value="90" lower_limit="70.2" upper_limit="115.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" lower_limit="15.6" upper_limit="28.8"/>
                    <measurement group_id="O2" value="21.6" lower_limit="16.2" upper_limit="28.7"/>
                    <measurement group_id="O3" value="26" lower_limit="18.9" upper_limit="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59</title>
        <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
        <time_frame>Day 50</time_frame>
        <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59</title>
          <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
          <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03</title>
        <description>The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer &lt;1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.</description>
        <time_frame>Days 29, 50, 121, and 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03</title>
          <description>The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer &lt;1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59</title>
        <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
        <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59</title>
          <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="5" upper_limit="5.2"/>
                    <measurement group_id="O2" value="5.5" lower_limit="5" upper_limit="6.1"/>
                    <measurement group_id="O3" value="5.1" lower_limit="5" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="5.1" upper_limit="7.3"/>
                    <measurement group_id="O2" value="6.6" lower_limit="5.7" upper_limit="7.7"/>
                    <measurement group_id="O3" value="6.4" lower_limit="5.6" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3" lower_limit="55.9" upper_limit="104"/>
                    <measurement group_id="O2" value="106.5" lower_limit="74.1" upper_limit="153"/>
                    <measurement group_id="O3" value="130.6" lower_limit="93.1" upper_limit="183.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="13.6" upper_limit="24.1"/>
                    <measurement group_id="O2" value="20.7" lower_limit="14.9" upper_limit="28.8"/>
                    <measurement group_id="O3" value="33.2" lower_limit="25.1" upper_limit="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="6" upper_limit="7.7"/>
                    <measurement group_id="O2" value="8.9" lower_limit="7.1" upper_limit="11.1"/>
                    <measurement group_id="O3" value="11.4" lower_limit="8.7" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59</title>
        <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
        <time_frame>Day 50</time_frame>
        <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59</title>
          <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
          <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4" lower_limit="55.6" upper_limit="102.4"/>
                    <measurement group_id="O2" value="103" lower_limit="72.1" upper_limit="147.2"/>
                    <measurement group_id="O3" value="124.3" lower_limit="87.9" upper_limit="175.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03</title>
        <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
        <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03</title>
          <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O2" value="5.2" lower_limit="4.9" upper_limit="5.6"/>
                    <measurement group_id="O3" value="5.2" lower_limit="5" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="5.2" upper_limit="6.7"/>
                    <measurement group_id="O2" value="8.3" lower_limit="6.7" upper_limit="10.3"/>
                    <measurement group_id="O3" value="8.4" lower_limit="6.6" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.2" lower_limit="119.9" upper_limit="241.7"/>
                    <measurement group_id="O2" value="302" lower_limit="218.9" upper_limit="416.7"/>
                    <measurement group_id="O3" value="316.7" lower_limit="246.2" upper_limit="407.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" lower_limit="33.4" upper_limit="61.1"/>
                    <measurement group_id="O2" value="57.7" lower_limit="42.5" upper_limit="78.4"/>
                    <measurement group_id="O3" value="69.7" lower_limit="53.1" upper_limit="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="18.3" upper_limit="34.2"/>
                    <measurement group_id="O2" value="28.1" lower_limit="20.1" upper_limit="39.2"/>
                    <measurement group_id="O3" value="32.9" lower_limit="24.4" upper_limit="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03</title>
        <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
        <time_frame>Day 50</time_frame>
        <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03</title>
          <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
          <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.8" lower_limit="115.7" upper_limit="231.9"/>
                    <measurement group_id="O2" value="274.9" lower_limit="195.3" upper_limit="386.9"/>
                    <measurement group_id="O3" value="313.1" lower_limit="243.1" upper_limit="403.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59</title>
        <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
        <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59</title>
          <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="5" upper_limit="5.2"/>
                    <measurement group_id="O2" value="5.1" lower_limit="5" upper_limit="5.2"/>
                    <measurement group_id="O3" value="5.3" lower_limit="4.8" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="5.1" upper_limit="6.3"/>
                    <measurement group_id="O2" value="5.6" lower_limit="5.1" upper_limit="6.1"/>
                    <measurement group_id="O3" value="5.6" lower_limit="5.2" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" lower_limit="33.7" upper_limit="67.1"/>
                    <measurement group_id="O2" value="60.5" lower_limit="40.5" upper_limit="90.4"/>
                    <measurement group_id="O3" value="74.5" lower_limit="53.3" upper_limit="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="10.2" upper_limit="16.6"/>
                    <measurement group_id="O2" value="15.1" lower_limit="11.2" upper_limit="20.4"/>
                    <measurement group_id="O3" value="20.9" lower_limit="15.6" upper_limit="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="6.7" upper_limit="9.1"/>
                    <measurement group_id="O2" value="11.3" lower_limit="8.6" upper_limit="14.8"/>
                    <measurement group_id="O3" value="13.6" lower_limit="10.1" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59</title>
        <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
        <time_frame>Day 50</time_frame>
        <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59</title>
          <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
          <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" lower_limit="33.8" upper_limit="66.5"/>
                    <measurement group_id="O2" value="58.6" lower_limit="39.4" upper_limit="87.2"/>
                    <measurement group_id="O3" value="71.1" lower_limit="50.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03</title>
        <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
        <time_frame>Screening, Day 29, Day 121, Day 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03</title>
          <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59</title>
        <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
        <time_frame>Screening, Day 29, Day 121, Day 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59</title>
          <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03</title>
        <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
        <time_frame>Screening, Day 29, Day 121, Day 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03</title>
          <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59</title>
        <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
        <time_frame>Screening, Day 29, Day 121, Day 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59</title>
          <description>The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer &gt;= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03</title>
        <description>The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer &lt;1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.</description>
        <time_frame>Day 29, Day 50, Day 121, Day 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03</title>
          <description>The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer &lt;1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59</title>
        <description>The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer &lt;1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.</description>
        <time_frame>Day 29, Day 50, Day 121, Day 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59</title>
          <description>The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer &lt;1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03</title>
        <description>The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer &lt;1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.</description>
        <time_frame>Day 29, Day 50, Day 121, Day 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03</title>
          <description>The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer &lt;1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59</title>
        <description>The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer &lt;1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.</description>
        <time_frame>Day 29, Day 50, Day 121, Day 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59</title>
          <description>The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer &lt;1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59</title>
        <description>The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer &lt;1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.</description>
        <time_frame>Day 29, Day 50, Day 121, Day 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59</title>
          <description>The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer &lt;1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03</title>
        <description>The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer &lt;1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.</description>
        <time_frame>Day 29, Day 50, Day 121, Day 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03</title>
          <description>The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer &lt;1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59</title>
        <description>The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer &lt;1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.</description>
        <time_frame>Day 29, Day 50, Day 121, Day 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59</title>
          <description>The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer &lt;1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03</title>
        <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
        <time_frame>Day 50</time_frame>
        <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03</title>
          <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
          <population>The immunogenicity full analysis population (IFAP) includes all participants who were randomized, received at least one vaccination, and had determinate assay results at any post-vaccination visit. Only participants with non-missing Day 50 results are included in this analysis.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.3" lower_limit="200.1" upper_limit="381.5"/>
                    <measurement group_id="O2" value="400.7" lower_limit="291.9" upper_limit="550.1"/>
                    <measurement group_id="O3" value="489.1" lower_limit="383" upper_limit="624.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Microneutralization (MN) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03</title>
        <description>Serum MN antibody titers against the H7 antigen (protein) contained in the vaccine. A higher MN titer means a better immune response to the vaccine.</description>
        <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Microneutralization (MN) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03</title>
          <description>Serum MN antibody titers against the H7 antigen (protein) contained in the vaccine. A higher MN titer means a better immune response to the vaccine.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O3" value="5" lower_limit="5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="5" upper_limit="5.5"/>
                    <measurement group_id="O2" value="6.2" lower_limit="5.6" upper_limit="6.9"/>
                    <measurement group_id="O3" value="6.3" lower_limit="5.5" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.2" lower_limit="147.4" upper_limit="274.6"/>
                    <measurement group_id="O2" value="274.3" lower_limit="197.4" upper_limit="381.2"/>
                    <measurement group_id="O3" value="286.3" lower_limit="218.1" upper_limit="375.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" lower_limit="40.8" upper_limit="64.7"/>
                    <measurement group_id="O2" value="58.1" lower_limit="44.6" upper_limit="75.6"/>
                    <measurement group_id="O3" value="66.6" lower_limit="53.4" upper_limit="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="22.2" upper_limit="38"/>
                    <measurement group_id="O2" value="29.7" lower_limit="22.7" upper_limit="38.8"/>
                    <measurement group_id="O3" value="34.4" lower_limit="27.6" upper_limit="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Microneutralization (MN) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59</title>
        <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
        <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Microneutralization (MN) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59</title>
          <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="5" upper_limit="5.1"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5.1"/>
                    <measurement group_id="O3" value="5" lower_limit="5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="4.9" upper_limit="5.5"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5.1"/>
                    <measurement group_id="O3" value="5.2" lower_limit="4.9" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="39.9" upper_limit="70.3"/>
                    <measurement group_id="O2" value="67.1" lower_limit="46.3" upper_limit="97.1"/>
                    <measurement group_id="O3" value="81.9" lower_limit="60.1" upper_limit="111.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="12.2" upper_limit="18.8"/>
                    <measurement group_id="O2" value="18.5" lower_limit="14.5" upper_limit="23.5"/>
                    <measurement group_id="O3" value="25.6" lower_limit="19.7" upper_limit="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="7" upper_limit="9.7"/>
                    <measurement group_id="O2" value="10.7" lower_limit="8.9" upper_limit="13"/>
                    <measurement group_id="O3" value="14" lower_limit="10.8" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Microneutralization (MN) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03</title>
        <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
        <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus AS03</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus AS03</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus AS03</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Microneutralization (MN) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03</title>
          <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="5.1"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O3" value="5.2" lower_limit="4.9" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="5.7" upper_limit="7.3"/>
                    <measurement group_id="O2" value="7.8" lower_limit="6.7" upper_limit="9.1"/>
                    <measurement group_id="O3" value="8.9" lower_limit="7.2" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.1" lower_limit="190.3" upper_limit="344.6"/>
                    <measurement group_id="O2" value="326.2" lower_limit="238.1" upper_limit="446.9"/>
                    <measurement group_id="O3" value="394.9" lower_limit="303.8" upper_limit="513.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4" lower_limit="44.9" upper_limit="76"/>
                    <measurement group_id="O2" value="71.6" lower_limit="53.6" upper_limit="95.6"/>
                    <measurement group_id="O3" value="95.4" lower_limit="73.3" upper_limit="124.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" lower_limit="23.7" upper_limit="41.9"/>
                    <measurement group_id="O2" value="34.4" lower_limit="26.1" upper_limit="45.4"/>
                    <measurement group_id="O3" value="41.1" lower_limit="32" upper_limit="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Microneutralization (MN) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59</title>
        <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
        <time_frame>Screening and Days 29, 50, 121 and 212</time_frame>
        <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
        <group_list>
          <group group_id="O1">
            <title>3.75 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O2">
            <title>7.5 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 µg Panblok H7 plus MF59</description>
          </group>
          <group group_id="O3">
            <title>15 µg Panblok H7 Plus MF59</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 µg Panblok H7 plus MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Microneutralization (MN) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59</title>
          <description>Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.</description>
          <population>Immunogenicity Per Protocol Population (IPPP) includes all participants who received a full dose of vaccine at Days 1 and 29 as assigned by randomization within protocol visit windows, had determinate assay results at Day 50 within protocol visit window, and had no major protocol deviations that may have an impact on immunogenicity assessments</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="5" upper_limit="5.2"/>
                    <measurement group_id="O2" value="5.3" lower_limit="5" upper_limit="5.6"/>
                    <measurement group_id="O3" value="5.1" lower_limit="5" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4/Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="5.2" upper_limit="6.5"/>
                    <measurement group_id="O2" value="6" lower_limit="5.3" upper_limit="6.7"/>
                    <measurement group_id="O3" value="5.9" lower_limit="5.4" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" lower_limit="51.4" upper_limit="88"/>
                    <measurement group_id="O2" value="87.1" lower_limit="59.8" upper_limit="126.9"/>
                    <measurement group_id="O3" value="113.8" lower_limit="80.4" upper_limit="161.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8/Day 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="12.5" upper_limit="19.8"/>
                    <measurement group_id="O2" value="20" lower_limit="15" upper_limit="26.6"/>
                    <measurement group_id="O3" value="27.1" lower_limit="20" upper_limit="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9/Day 212</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="7.3" upper_limit="10.5"/>
                    <measurement group_id="O2" value="11.5" lower_limit="9.2" upper_limit="14.4"/>
                    <measurement group_id="O3" value="15.2" lower_limit="11.6" upper_limit="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>13 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>3.75 ug Panblok H7 Plus AS03</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 plus AS03</description>
        </group>
        <group group_id="E2">
          <title>7.5 ug Panblok H7 Plus AS03</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with AS03</description>
        </group>
        <group group_id="E3">
          <title>15 ug Panblok H7 Plus AS03</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with AS03</description>
        </group>
        <group group_id="E4">
          <title>3.75 ug Panblok H7 Plus MF59</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 adjuvanted with MF59</description>
        </group>
        <group group_id="E5">
          <title>7.5 ug Panblok H7 Plus MF59</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with MF59</description>
        </group>
        <group group_id="E6">
          <title>15 ug Panblok H7 Plus MF59</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with MF59</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pulmonary artery stenosis congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Colloid brain cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E5" events="15" subjects_affected="10" subjects_at_risk="60"/>
                <counts group_id="E6" events="9" subjects_affected="8" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="62"/>
                <counts group_id="E4" events="18" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="62"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="60"/>
                <counts group_id="E3" events="24" subjects_affected="19" subjects_at_risk="62"/>
                <counts group_id="E4" events="22" subjects_affected="16" subjects_at_risk="61"/>
                <counts group_id="E5" events="13" subjects_affected="11" subjects_at_risk="60"/>
                <counts group_id="E6" events="11" subjects_affected="10" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="70" subjects_affected="42" subjects_at_risk="62"/>
                <counts group_id="E2" events="68" subjects_affected="42" subjects_at_risk="60"/>
                <counts group_id="E3" events="60" subjects_affected="36" subjects_at_risk="62"/>
                <counts group_id="E4" events="44" subjects_affected="32" subjects_at_risk="61"/>
                <counts group_id="E5" events="42" subjects_affected="29" subjects_at_risk="60"/>
                <counts group_id="E6" events="45" subjects_affected="29" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="62"/>
                <counts group_id="E2" events="27" subjects_affected="19" subjects_at_risk="60"/>
                <counts group_id="E3" events="24" subjects_affected="18" subjects_at_risk="62"/>
                <counts group_id="E4" events="23" subjects_affected="16" subjects_at_risk="61"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E6" events="17" subjects_affected="13" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="29" subjects_affected="21" subjects_at_risk="62"/>
                <counts group_id="E2" events="26" subjects_affected="17" subjects_at_risk="60"/>
                <counts group_id="E3" events="23" subjects_affected="16" subjects_at_risk="62"/>
                <counts group_id="E4" events="20" subjects_affected="16" subjects_at_risk="61"/>
                <counts group_id="E5" events="28" subjects_affected="16" subjects_at_risk="60"/>
                <counts group_id="E6" events="21" subjects_affected="15" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Silvija Tresnjak-Smith</name_or_title>
      <organization>BARDA</organization>
      <phone>202-557-1993</phone>
      <email>Silvija.Tresnjak-Smith@hhs.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03283319
org study id: BP-I-17-002
secondary id: HHSO100201400004I
secondary id: TO# HHSO10033001T
nct id: NCT03283319
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
The main purpose of this study is to assess the safety and ability of a Panblok H7 influenza
      vaccine adjuvanted with AS03 or MF59 to generate an immune response after 2 doses separated
      by 28 days. Three different antigen dose levels of Panblok H7 will be tested.
This is a randomized, double-blinded, phase 2 study to assess safety and immunogenicity of
      Panblok H7 vaccine at three antigen dose levels (3.75, 7.5, and 15 μg) adjuvanted with AS03
      or MF59. The main purpose of this study is to assess the safety and ability of the
      recombinant Panblok H7 influenza vaccine adjuvanted with AS03 or MF59 to generate an immune
      response after 2 doses separated by 28 days in healthy males and nonpregnant females, aged 18
      to 49 years, inclusive. The expected study duration is approximately 13.5 months per
      participant.
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: Participants will be randomized to one of the six treatment groups at Day 1 and will receive the assigned dose of antigen and adjuvant on Day 1 and Day 29.
primary purpose: Prevention
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Solicited Local Reactogenicity Symptoms for Participants Given Adjuvant AS03
time frame: Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)
description: Count of participants who experienced at least one of the following during at least one of the time frames specified:
Solicited local reactions at the injection site: erythema/redness, induration/swelling, and pain
measure: Solicited Systemic Reactogenicity Symptoms for Participants Given Adjuvant AS03
time frame: Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)
description: Count of participants who experienced at least one of the following during at least one of the time frames specified:
Solicited systemic reactions include fever, myalgia (muscle pain), arthralgia (joint pain), fatigue, headache, nausea, vomiting, diarrhea, and chills.
measure: Solicited Local Reactogenicity Symptoms for Participants Given Adjuvant MF59
time frame: Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)
description: Count of participants who experienced at least one of the following during at least one of the time frames specified:
Solicited local reactions at the injection site: erythema/redness, induration/swelling, and pain
measure: Solicited Systemic Reactogenicity Symptoms for Participants Given Adjuvant MF59
time frame: Day 1-8, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)
description: Count of participants who experienced at least one of the following during at least one of the time frames specified:
Solicited systemic reactions include fever, myalgia (muscle pain), arthralgia (joint pain), fatigue, headache, nausea, vomiting, diarrhea, and chills.
measure: Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03
time frame: Day 50
description: The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.
measure: Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59
time frame: Day 50
description: The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.
measure: Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03
time frame: Day 50
description: The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.
measure: Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59
time frame: Day 50
description: The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.
measure: Treatment-emergent Serious Adverse Events (SAEs) for Participants Given Adjuvant AS03
time frame: Day 1 through Day 394
description: Count of participants who experienced at least one serious adverse event
measure: Treatment-emergent Serious Adverse Events (SAEs) for Participants Given Adjuvant MF59
time frame: Day 1 through Day 394
description: Count of participants who experienced at least one serious adverse event
measure: Treatment-emergent Medically Attended Adverse Events (MAAEs) for Participants Given Adjuvant AS03
time frame: Day 1 through Day 394
description: Count of participants who experienced at least one adverse event that requires a visit to medical personnel, including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason occurring post-vaccination.
measure: Treatment-emergent Medically Attended Adverse Events (MAAEs) for Participants Given Adjuvant MF59
time frame: Day 1 through Day 394
description: Count of participants who experienced at least one adverse event that requires a visit to medical personnel, including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason occurring post-vaccination.
measure: Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs) for Participants Given Adjuvant AS03
time frame: Day 1 through Day 394
description: Count of participants who experienced at least one medical condition that was potentially immune mediated occurring post-vaccination
measure: Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs) for Participants Given Adjuvant MF59
time frame: Day 1 through Day 394
description: Count of participants who experienced at least one medical condition that was potentially immune mediated occurring post-vaccination
measure: Treatment-emergent Unsolicited Adverse Events for Participants Given Adjuvant AS03
time frame: Day 1 through Day 53, which is the upper window of the Day 50 visit
description: Count of participants who experienced at least one unsolicited adverse event (i.e. adverse events not included in the solicited local and systemic adverse event list nor considered a serious AE, MAAE or PIMMC ) that occur post-vaccination.
measure: Treatment-emergent Unsolicited Adverse Events for Participants Given Adjuvant MF59
time frame: Day 1 through Day 50
description: Count of participants who experienced at least one unsolicited adverse event (i.e. adverse events not included in the solicited local and systemic adverse event list nor considered a serious AE, MAAE or PIMMC) that occur post-vaccination.
measure: Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03
time frame: Day 50
description: The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.
measure: Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59
time frame: Day 50
description: The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.
measure: Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03
time frame: Day 50
description: The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.
measure: Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03
time frame: Screening and Days 29, 50, 121 and 212
description: Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.
measure: Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59
time frame: Day 50
description: The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.
measure: Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03
time frame: Days 29, 50, 121, and 212
description: The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer <1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.
measure: Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59
time frame: Screening and Days 29, 50, 121 and 212
description: Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.
measure: Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59
time frame: Day 50
description: Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.
measure: Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03
time frame: Screening and Days 29, 50, 121 and 212
description: Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.
measure: Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03
time frame: Day 50
description: Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.
measure: Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59
time frame: Screening and Days 29, 50, 121 and 212
description: Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.
measure: Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59
time frame: Day 50
description: Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.
measure: Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03
time frame: Screening, Day 29, Day 121, Day 212
description: The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.
measure: Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59
time frame: Screening, Day 29, Day 121, Day 212
description: The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.
measure: Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03
time frame: Screening, Day 29, Day 121, Day 212
description: The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.
measure: Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59
time frame: Screening, Day 29, Day 121, Day 212
description: The percentage of participants achieving seroprotection, defined as a serum HAI antibody titer >= 1:40 against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine. A titer of 1:40 or greater is considered to be a sufficient amount of antibody to avoid influenza infection in half of exposed individuals.
measure: Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03
time frame: Day 29, Day 50, Day 121, Day 212
description: The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer <1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.
measure: Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59
time frame: Day 29, Day 50, Day 121, Day 212
description: The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer <1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.
measure: Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03
time frame: Day 29, Day 50, Day 121, Day 212
description: The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer <1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.
measure: Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59
time frame: Day 29, Day 50, Day 121, Day 212
description: The percentage of participants obtaining seroconversion based on HAI antibody titers, defined as either a prevaccination HAI titer <1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a minimum 4 fold rise in postvaccination HAI titer. Seroconversion represents the minimum intended effect of vaccination.
measure: Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59
time frame: Day 29, Day 50, Day 121, Day 212
description: The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer <1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.
measure: Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03
time frame: Day 29, Day 50, Day 121, Day 212
description: The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer <1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.
measure: Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59
time frame: Day 29, Day 50, Day 121, Day 212
description: The percentage of participants obtaining seroconversion based on MN antibody titers, defined as either a prevaccination MN titer <1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a minimum 4 fold rise in postvaccination MN titer. Seroconversion represents the minimum intended effect of vaccination.
measure: Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03
time frame: Day 50
description: Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.
measure: Serum Microneutralization (MN) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03
time frame: Screening and Days 29, 50, 121 and 212
description: Serum MN antibody titers against the H7 antigen (protein) contained in the vaccine. A higher MN titer means a better immune response to the vaccine.
measure: Serum Microneutralization (MN) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59
time frame: Screening and Days 29, 50, 121 and 212
description: Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.
measure: Serum Microneutralization (MN) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03
time frame: Screening and Days 29, 50, 121 and 212
description: Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.
measure: Serum Microneutralization (MN) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59
time frame: Screening and Days 29, 50, 121 and 212
description: Serum HAI antibody titers against the H7 antigen (protein) contained in the vaccine. A higher HAI titer means a better immune response to the vaccine.
arm group label: 3.75 ug Panblok H7 plus AS03
arm group type: Experimental
description: Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 plus AS03
arm group label: 7.5 ug Panblok H7 plus AS03
arm group type: Experimental
description: Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with AS03
arm group label: 15 ug Panblok H7 plus AS03
arm group type: Experimental
description: Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with AS03
arm group label: 3.75 ug Panblok H7 plus MF59
arm group type: Experimental
description: Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 adjuvanted with MF59
arm group label: 7.5 ug Panblok H7 plus MF59
arm group type: Experimental
description: Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with MF59
arm group label: 15 ug Panblok H7 plus MF59
arm group type: Experimental
description: Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with MF59
intervention type: Biological
intervention name: 3.75 ug Panblok H7
description: 0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.
arm group label: 3.75 ug Panblok H7 plus AS03
arm group label: 3.75 ug Panblok H7 plus MF59
intervention type: Biological
intervention name: 7.5 ug Panblok H7
description: Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.
arm group label: 7.5 ug Panblok H7 plus AS03
arm group label: 7.5 ug Panblok H7 plus MF59
intervention type: Biological
intervention name: 15 ug Panblok H7
description: Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.
arm group label: 15 ug Panblok H7 plus AS03
arm group label: 15 ug Panblok H7 plus MF59
intervention type: Biological
intervention name: MF59
description: 0.5 mL MF59 (39 mg squalene/mL ) adjuvant.
arm group label: 15 ug Panblok H7 plus MF59
arm group label: 3.75 ug Panblok H7 plus MF59
arm group label: 7.5 ug Panblok H7 plus MF59
intervention type: Biological
intervention name: AS03
description: 0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.
arm group label: 15 ug Panblok H7 plus AS03
arm group label: 3.75 ug Panblok H7 plus AS03
arm group label: 7.5 ug Panblok H7 plus AS03
criteria: 
gender: All
minimum age: 18 Years
maximum age: 49 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Mark Adams, MD
role: Principal Investigator
affiliation: Central Kentucky Research
last name: Matthew Davis, MD
role: Principal Investigator
affiliation: Rochester Clinical Research, Inc.
last name: Carlos Fierro, MD
role: Principal Investigator
affiliation: Johnson County Clin-Trials
last name: Terry Poling, MD
role: Principal Investigator
affiliation: Heartland Research Associates
facility: 
facility: 
facility: 
facility: 
country: United States
responsible party type: Sponsor
mesh term: Influenza, Human
sharing ipd: No
provided document: 
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 